logo
Light-powered robot swarms may replace antibiotics for tough sinus infections

Light-powered robot swarms may replace antibiotics for tough sinus infections

Yahoo3 days ago
Swarms of microrobots have been designed to help get rid of bacterial sinus infections. After completing the task, these tiny robots can be easily expelled from the nose.
Interestingly, these tiny, light-activated robots are reportedly as small as a "dust speck."
These are called CBMRs (copper single–atom–loaded bismuth oxoiodide photocatalytic microrobots).
The China-Hong Kong team has successfully inserted newly developed microrobots into animal sinuses during preclinical trials to treat bacterial infections.
'Our proposed microrobotic therapeutic platform offers the advantages of noninvasiveness, minimal resistance, and drug-free intervention,' the researchers from Guangxi University, Shenzhen University, and the Chinese University of Hong Kong stated.
Chronic sinusitis treatments have long been problematic, offering a choice between invasive surgery and often ineffective drug delivery.
In the past, magnetic microrobots have been created, but it's tough for them to move through inflamed areas in the body that are clogged with thick pus and cellular debris.
Driven by the limitations of current treatments, scientists, under the leadership of Haidong Yu, engineered these light-activated microbots to combat deep-seated bacterial infections in the sinuses effectively.
Researchers first created tiny magnetic particles (CBMRs) containing antibacterial copper. They then built a special magnetically guided optical fiber to both control the movement of these microrobots and shine visible light on them.
Here's how these tiny bots work.
Reportedly, microrobot swarms are injected into the sinus cavity through the nostril duct.
A magnetic field can precisely steer them, navigating even the most inflamed and viscous sinus environments directly to the infection site.
'They constructed a magnetically guided optical fiber that could coordinate the movements of CBMR swarms and illuminate them with visible light. Under a magnetic field, CBMRs exert collective mechanical forces that disrupt bacterial cell walls,' the team explained.
Once in place, this designed optical fiber shines visible light, activating the CBMRs, and causing them to release heat for better movement.
When activated by light, these microrobots perform two key functions: they exert collective mechanical forces to break apart robust bacterial biofilms.
Moreover, they generate antibacterial reactive oxygen species (ROS), which are free radicals that effectively kill the now-exposed bacteria.
The team tested the microbots on animal models.
In preclinical trials, these microrobots proved highly effective: they eliminated bacterial biofilms in lab settings and successfully cleared infections in rabbit models of sinusitis.
Moreover, CBMRs were shown to effectively clear bacteria from pig sinuses outside of a living body.
Remarkably, these positive outcomes occurred without tissue damage or side effects, and the microrobots were even naturally expelled from the nose.
The team says this new approach comes with various benefits.
As it's non-invasive, the technique eliminates the need for complex surgeries. Moreover, it promotes minimal resistance since it doesn't depend on traditional drugs, thereby reducing the risk of antibiotic resistance. Essentially, it offers a novel, drug-free intervention for fighting infections.
'The authors propose that their approach could be applied to treat other sinus-related diseases,' the press release noted.
The findings were published in the journal Science Robotics.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Love, Robots, and the Future: 12th International Love and Sex with Robots Conference Heads to China
Love, Robots, and the Future: 12th International Love and Sex with Robots Conference Heads to China

Associated Press

time40 minutes ago

  • Associated Press

Love, Robots, and the Future: 12th International Love and Sex with Robots Conference Heads to China

Los Angeles, CA July 03, 2025 --( )-- The 12th International Love and Sex with Robots Conference is set to take place from June 24–26, 2026, marking a significant milestone in the event's evolution since its inaugural gathering in London. Hosted in Shaoxing, China, this highly anticipated edition will bring together leading researchers, scientists, and industry innovators to explore the future of intimacy, companionship, and emotional connection through robotics and artificial intelligence. The conference will spotlight pioneering research and critical discourse on topics such as ethical considerations in human-robot relationships, emotional AI, robotic intimacy, virtual and augmented reality experiences, and the sociocultural impact of humanoid robotics. Featured speakers include Professor Ken Mogi, a renowned Japanese neuroscientist, author, and broadcaster known for his work on consciousness and the science of happiness, and Professor Zhigeng Pan, Dean of the School of Artificial Intelligence at Nanjing University of Information Science and Technology (NUIST), whose research in virtual reality and the metaverse has gained international recognition. Additional experts from institutions such as MIT, Stanford, and Tsinghua University will join these thought leaders, along with technology pioneers from companies including Tesla, Google, and Alibaba. The conference is also expected to host policymakers from China, the United Kingdom, and the European Union, emphasizing the global relevance and interdisciplinary collaboration necessary for the development of emotionally intelligent robotics. Media professionals are invited to attend the conference either virtually at no cost or in person in China with access to a special two-for-one ticket offer. This is a unique opportunity to engage directly with the world's foremost experts in AI, robotics, and human-technology interaction. Official conference website: For additional details or press inquiries, please contact: Emma Yann Zhang, General Chair Email: [email protected] Phone: +86 187 0514 5004 Contact Information: Love and Sex with Robots Conference Emma Yann Zhang +8618705140421 Contact via Email Read the full story here: Love, Robots, and the Future: 12th International Love and Sex with Robots Conference Heads to China Press Release Distributed by

CPSC Warns Consumers to Immediately Stop Using AIRLYA-Life Infant Walkers Due to Risk of Serious Injury or Death from Fall and Entrapment Hazards; Violation of the Mandatory Standard for Infant Walkers
CPSC Warns Consumers to Immediately Stop Using AIRLYA-Life Infant Walkers Due to Risk of Serious Injury or Death from Fall and Entrapment Hazards; Violation of the Mandatory Standard for Infant Walkers

Associated Press

timean hour ago

  • Associated Press

CPSC Warns Consumers to Immediately Stop Using AIRLYA-Life Infant Walkers Due to Risk of Serious Injury or Death from Fall and Entrapment Hazards; Violation of the Mandatory Standard for Infant Walkers

WASHINGTON, July 3, 2025 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is warning consumers to immediately stop using AIRLYA-Life Infant Walkers because they pose a risk of serious injury or death from fall and entrapment hazards. The infant walkers can fit through a standard doorway and fail to stop at the edge of a step. Also, the walkers have leg openings that can allow the child to slip down until the child's head becomes entrapped. These are violations of the mandatory safety standard for infant walkers. CPSC issued a Notice of Violation to Qingdaoapuapukuajingdianzishangwuyouxiangongsi, of China, doing business as Childcrew. Childcrew is the Amazon seller and has not agreed to recall these products or offer a remedy to consumers. About 9,935 infant walkers were sold online on Amazon from April 2023 through April 2025 for between $63 and $100. The infant walkers may have also been sold on other websites and by various third-party sellers. The infant walkers have adjustable height settings and six wheels. They come in green with a black push handle and gray seat. 'AIRLYA-Life' and 'Model No: CLDXBC-01" are printed on a label located under the seat. CPSC is aware the firm also sold the infant walkers in black, pink and white. These products were manufactured in China. CPSC urges consumers to stop using the infant walkers immediately and dispose of them. Do not sell or give away these hazardous infant walkers. Report any incidents involving injury or product defect to CPSC at Note: Individual Commissioners may have statements related to this topic. Please visit to search for statements related to this or other topics. About the U.S. CPSC The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury associated with the use of thousands of types of consumer products. Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually. Since the CPSC was established more than 50 years ago, it has worked to ensure the safety of consumer products, which has contributed to a decline in injuries associated with these products. Federal law prohibits any person from selling products subject to a Commission ordered recall or a voluntary recall undertaken in consultation with the CPSC. For lifesaving information: - Visit - Sign up to receive our e-mail alerts. - Follow us on Facebook, Instagram, X, BlueSky, Threads, LinkedIn and Truth Social. - Report a dangerous product or a product-related injury on - Call CPSC's Hotline at 800-638-2772 (TTY 800-638-8270). - Contact a media specialist. Release Number: 25-370 View original content to download multimedia: SOURCE U.S. Consumer Product Safety Commission

Oscar Health: Should You Buy OSCR Stock At $17?
Oscar Health: Should You Buy OSCR Stock At $17?

Forbes

time2 hours ago

  • Forbes

Oscar Health: Should You Buy OSCR Stock At $17?

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Oscar Health, Inc. is displayed ... More on a smartphone screen, with the company's branding visible in the background, on May 04, 2025, in Chongqing, China. (Photo illustration by) On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified? This announcement caused turmoil in the market, leading to a 40% plunge in Centene's stock. Other significant players also faced considerable declines: Oscar Health (NYSE: OSCR) decreased by 19%, UnitedHealth (NYSE: UNH) dropped 6%, Molina (MOH) fell 22%, and CVS (CVS) saw a decrease of 4%. The primary issue confronting these insurers is a legitimate one: increasing medical costs are diminishing their profits. This rise in expenses is due to various factors, including a higher number of less healthy individuals enrolling, an uptick in the volume of medical procedures, and persistently high prices for drugs. Given these industry-wide difficulties, a critical question for investors is whether Oscar Health's stock, currently priced around $17, represents a buying opportunity. Although OSCR has risen 23% year-to-date, it is still trading 30% below its 52-week peak of over $23. We believe that OSCR stock represents a solid choice at its current price of $17. Our conclusion is drawn from a thorough analysis of Oscar Health's current valuation in relation to its recent operational performance as well as its historical and present financial health. Our detailed evaluation of Oscar Health emphasizes essential factors: Growth, Profitability, Financial Stability, and Downturn Resilience. Our analysis reveals that the company has moderate operational performance and financial condition, yet its current valuation is appealing, which we explain in more detail below. However, for those seeking upside with lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and delivering returns exceeding 91% since its launch. Separately, refer to – UnitedHealth: Buy Or Sell UNH Stock At $325? How Does Oscar Health's Valuation Compare to The S&P 500? When considering what you pay per dollar of sales or profit, OSCR stock appears slightly undervalued in relation to the broader market. How Have Oscar Health's Revenues Evolved in Recent Years? Oscar Health's Revenues have increased significantly over the past few years. How Profitable Is Oscar Health? Oscar Health's profit margins are significantly lower than most companies within the Trefis coverage universe. Is Oscar Health Financially Stable? Oscar Health's balance sheet appears quite robust. How Resilient Is OSCR Stock During A Downturn? OSCR stock has performed significantly worse than the benchmark S&P 500 index during several recent downturns. As investors hope for a gentle landing by the U.S. economy, how severe could the situation be if another recession occurs? Our dashboard How Low Can Stocks Go During A Market Crash shows how crucial stocks performed during and after the last six market crashes. Summarizing the Findings: Implications for OSCR Stock In conclusion, Oscar Health's performance across the previously mentioned criteria is as follows: In summary, Oscar Health has shown a moderate performance across the essential criteria of Growth, Profitability, Financial Stability, and Downturn Resilience. Although its profit margins seem modest compared to the broader market, this is common for the health insurance sector, which generally operates on thin margins and high volumes. This industry-wide trait is also reflected in valuation standards. For example, Centene and CVS trade at 0.2 times their revenue, Molina at 0.4 times, and UnitedHealth (UNH) at 0.7 times. Despite these industry standards, we contend that Oscar Health's technological framework and robust revenue growth justify a higher valuation multiple than that of several more traditional insurance competitors. Overall, we consider it a solid choice at present levels. However, it is crucial to recognize potential risks. Investors may be reluctant to assign a higher multiple due to the naturally slim margins in the industry and the stock's volatility. Thus, investors should carefully assess these risks before making a decision to invest in Oscar Health. There always exists a significant risk when investing in a single stock, or merely a few. Consider Trefis High Quality (HQ) Portfolio which, comprising 30 stocks, has a history of consistently outperforming the S&P 500 over the last 4-year span. What accounts for this? Collectively, HQ Portfolio stocks yielded superior returns with reduced risk compared to the benchmark index; less of a roller-coaster experience, as evidenced in HQ Portfolio performance metrics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store